Astrana Health Inc (ASTH) valuation
Astrana Health P/E ratio history
Astrana Health trades at 44.6 times its earnings over the last twelve months and 10.9 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 18.1 (year to Dec 2020) to 68.5 (year to Dec 2018), with a median of 35.0.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $24.81 | $0.46 | 53.9 | 18.7 |
| Dec 31, 2024 | $31.53 | $0.90 | 35.0 | 20.6 |
| Dec 31, 2023 | $38.30 | $1.29 | 29.7 | — |
| Dec 31, 2022 | $29.59 | $0.98 | 30.2 | — |
| Dec 31, 2021 | $73.48 | $1.51 | 48.7 | — |
| Dec 31, 2020 | $18.27 | $1.01 | 18.1 | — |
| Dec 31, 2019 | $18.41 | $0.37 | 49.8 | — |
| Dec 31, 2018 | $19.85 | $0.29 | 68.5 | — |
| Dec 31, 2017 | $24.00 | $0.90 | 26.7 | — |
| Dec 31, 2016 | $7.50 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Astrana Health valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Astrana HealthASTH | $2.04B | 44.6 | 10.9 | 0.5 |
| SchrodingerSDGR | $2.03B | — | — | 7.8 |
| FortreaFTRE | $2.02B | — | 19.8 | 0.8 |
| Genedx HoldingsWGS | $2.05B | — | 104.1 | 4.5 |
| Maravai LifesciencesMRVI | $2.02B | — | — | 9.7 |
| VericelVCEL | $2.06B | 83.9 | 59.2 | 6.7 |
| ImmunomeIMNM | $2.06B | — | — | — |
| SepternaSEPN | $1.98B | — | — | 20.1 |
| ZymeworksZYME | $2.09B | — | 24.1 | 56.3 |
| Peer median | 83.9 | 41.6 | 7.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ASTH financials · ASTH returns
No forecast, no recommendation. This page describes Astrana Health Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.